The clinical management of neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) may significantly change this year as many pivotal phase 3 clinical trial results will be announced. In fact, as our readers open this issue, the results from the SOL-1 phase 3 clinical trial of OTX-TKI (Axpaxli; Ocular Therapeutix) will have been released a few weeks earlier. It will be exciting to see how tyrosine kinase inhibitors (TKIs) may fit into our treatment armamentarium.

Bringing a novel drug from phase 1 to phase 3 trials is an accomplishment in itself, with a timeline that can take a decade or more. It is estimated¹ that only 10% of investigational drugs are able to reach phase 3. Clinical trials are made possible by the dedication of physicians, scientists, industry collaborators, study coordinators, and patients who selflessly volunteer. Like many of you, I eagerly await all the exciting phase 3 trial readouts. In addition, I look forward to actively discussing the data with colleagues at upcoming retina meetings.

As I read this issue of Retinal Physician, I am very appreciative of the knowledge being shared by so many leaders in our field. Drs. David Boyer and Simrat Sodhi discuss OTX-TKI and other TKIs, such as the vorolanib intravitreal insert (Duravyu; EyePoint Pharmaceuticals), that are in late-stage clinical trials. Drs. Giulia Gregori and Jay Chhablani share insights on diagnosing and managing polypoidal choroidal vasculopathy. This issue also has articles on dry AMD. Drs. Michael Colucciello, Tiago Rassi, and Daniel M. Berinstein discuss the current evidence for photobiomodulation and the questions surrounding this treatment for intermediate dry AMD. Dr. Jessica Randolph and Benedict Uzorka review the therapeutic pipeline for geographic atrophy (GA). Furthermore, Dr. Thomas Ciulla takes a deeper dive into dual-pathway gene therapy for GA. This issue also includes a column in which Drs. John Gonzalez, Jessica Shantha, Sruthi Arepalli, Edmund Tsui, and Paulina Liberman share their thoughts on why uveitis fellowship deserves a second look. Finally, Elizabeth Cifers shares a refresher on proper coding for wet and dry AMD.

I appreciate all our contributors who have graciously shared their knowledge. Their hard work and generosity is essential to the success of this journal. Thank you for taking the time to read Retinal Physician—I am grateful for your partnership. RP